CD8 Antibody (YTS105.18)

CD8, also known as Leu-2 or T8 in human and Lyt2 or Lyt3 in mouse, is a cell surface glycoprotein belonging to the immunoglobulin supergene family (1, 2). CD8 is expressed on cytotoxic T-lymphocytes (T-cells), most thymocytes, between 35-45% of peripheral blood lymphocytes, and a population of natural killer (NK) cells (1, 2). The CD8 molecule consists of disulfide-linked alpha (alpha) and beta (beta) chains that present on T-cells as either CD8alphaalpha homodimers or CD8alphabeta heterodimers (1, 3). Both alpha and beta chains consist of a signaling sequence, an extracellular Ig-like domain, a membrane proximal stalk region, a transmembrane domain, and a cytoplasmic tail (3). Human CD8alpha is processed as 235 amino acids (aa) in length with a theoretical molecular weight of ~26 kDa, while mouse CD8alpha is 247 aa and has a theoretical molecular weight of 27.5 kDa (4, 5). Functionally, CD8 acts as an antigen coreceptor on cytotoxic T-cells and interacts with the major histocompatibility complex (MHC) class I molecules on antigen presenting cells (APCs), mediating cell-cell interactions within the immune system. Conversely, CD4 molecules interact with antigens presented on MHC class II molecules and are activated to become helper T-cells (TH) (1,2). Interestingly, thymocytes can transiently express both CD4 and CD8 during the maturation process (2). Furthermore, the cytoplasmic tail of CD8 has a Lck (lymphocyte-specific protein tyrosine kinase) binding domain where Lck interacts with CD8, initiating a phosphorylation cascade that activates transcription factors and promotes T-cell activation (6). More specifically, CD8alphabeta functions as a T-cell co-receptor, while CD8alphaalpha promotes T-cell survival and differentiation (7).

Given its role in the immune system, CD8-deficiency in T-cells is a hallmark of many diseases and pathologies (8-10). Specifically, CD8+ T-cell deficiency is prevalent in chronic autoimmune diseases including multiple sclerosis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, type 1 diabetes mellitus, and Graves' disease (8). Furthermore, cancers or chronic infection can lead to CD8 T-cell exhaustion as the continual antigen presentation and inflammatory signals eventually cause the CD8+ T-cells to lose functionality (9, 10). However, animal models and clinical studies have suggested that T-cells are capable of being reinvigorated using inhibitory receptor blockade resulting in better disease outcomes and these exhausted T-cells may be a potential therapeutic target (9, 10).

Alternative names for CD8 includes CD antigen: CD8a, CD8 antigen, alpha polypeptide (p32), CD8a molecule, CD8A, Leu2 T-lymphocyte antigen, LEU2, MAL, OKT8 T-cell antigen, p32, T cell co-receptor, T8 T-cell antigen, T-cell antigen Leu2, T-cell surface glycoprotein CD8 alpha chain, and T-lymphocyte differentiation antigen T8/Leu-2.

References

1. Littman D. R. (1987). The structure of the CD4 and CD8 genes. Annual review of immunology. https://doi.org/10.1146/annurev.iy.05.040187.003021

2. Naeim F. (2008). Chapter 2- Principles of Immunophenotyping. Hematopathology. https://doi.org/10.1016/B978-0-12-370607-2.00002-8.

3. Gao, G. F., & Jakobsen, B. K. (2000). Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. Immunology today. https://doi.org/10.1016/s0167-5699(00)01750-3

4. UniProt (P01732)

5. UniProt (P01731)

6. Kappes D. J. (2007). CD4 and CD8: hogging all the Lck. Immunity. https://doi.org/10.1016/j.immuni.2007.11.002

7. Gangadharan, D., & Cheroutre, H. (2004). The CD8 isoform CD8alphaalpha is not a functional homologue of the TCR co-receptor CD8alphabeta. Current opinion in immunology. https://doi.org/10.1016/j.coi.2004.03.015

8. Pender M. P. (2012). CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis. Autoimmune diseases. https://doi.org/10.1155/2012/189096

9. Kurachi M. (2019). CD8+ T cell exhaustion. Seminars in immunopathology. https://doi.org/10.1007/s00281-019-00744-5

10. Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018). CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annual review of medicine. https://doi.org/10.1146/annurev-med-012017-043208

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 2 applications: IF/IHC, IHC-P.

Showing Publications 1 - 10 of 14. Show All 14 Publications. Collapse Publications.

Publications using NB200-578	Applications	Species
Lin XT, Zhang J, Liu ZY et al. Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice Cell reports 2023-07-25 [PMID: 37450367] (IHC-P, Mouse)	IHC-P	Mouse
O'Connor M, Kallenberg D, Camilli C Et al. LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency Med (N Y) 2022-05-19 [PMID: 35590198]
Wu Q, Huang Q, Jiang Y et al. Remodeling Chondroitin-6-Sulfate-Mediated Immune Exclusion Enhances Anti-PD-1 Response in Colorectal Cancer with Microsatellite Stability Cancer Immunology Research 2022-02-01 [PMID: 34933913]
Priego N, Zhu L, Monteiro C et al. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis Nat. Med. 2018-06-11 [PMID: 29892069] (Human)		Human
Ji H, Zheng W et al. Sex-specific T-cell regulation of angiotensin II-dependent hypertension. Hypertension 2014-01-09 [PMID: 24935938] (IF/IHC, Mouse)	IF/IHC	Mouse
Nakashima, H et al. A Novel Combination Immunotherapy for Cancer by IL-13Ra2-Targeted DNA Vaccine and Immunotoxin in Murine Tumor Models. J Immunol 187: 4935-46. 2011-01-01 [PMID: 22013118]
Lacroix-Lamande, S et al. Neonate intestinal immune response to CpG oligodeoxynucleotide stimulation. PLoS One 4: 1-8. 2009-01-01 [PMID: 20011519]
Karlsson, MR et al. Hypersensitivity and oral tolerance in the absence of a secretory immune system. Allergy 65: 561-70. 2010-01-01 [PMID: 19886928]
Auray, G et al. (2007) Involvement of intestinal epithelial cells in dendritic cell recruitment during C. parvum infection Microbes Infect 9: 574-82. 2007-01-01 [PMID: 17395519]
Himoudi, N et al. (2007) Development of anti-PAX3 immune responses; a target for cancer immunotherapy. Cancer Immunol Immunother 56: 1381-95. 2007-01-01 [PMID: 17318653]
Sroga, JM et al. Rats and mice exhibit distinct inflammatory reactions after spinal cord injury. J Comp Neurol. 462: 223-40. 2003-01-01 [PMID: 12794745]
Wise, MP et al. Cutting edge: Linked suppression of skin graft rejection can operate through indirect recognition. J Immunol 161: 5813-5816. 1998-01-01 [PMID: 9834057]
Cobbold, SP et al. The induction of skin graft tolerance in MHC-mis matched or primed recipients: primed T-cells can be tolerized in the periphery with CD4 and CD8 antibodies. Eur. J. Immunol. 20: 2747-2755. 1990-01-01 [PMID: 1980112]
Qin, S et al. (1990) Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur. J. Immunol. 20: 2737-2745. 1990-01-01 [PMID: 1702726]
Show All 14 Publications. Collapse Publications.

Array NB200-578

• CD8 Antibodies
• CD8 Antibody Pairs
• CD8 ELISA Kits
• CD8 Lysates
• CD8 Proteins
• CD8 Proteins and Enzymes
• CD8 ELISA